Burney Co. Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Burney Co. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 46.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,237 shares of the medical research company’s stock after buying an additional 390 shares during the period. Burney Co.’s holdings in Thermo Fisher Scientific were worth $616,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the period. Port Capital LLC lifted its position in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company’s stock worth $721,000 after purchasing an additional 22 shares during the period. Clark Capital Management Group Inc. lifted its position in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company’s stock worth $2,312,000 after purchasing an additional 23 shares during the period. Monograph Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company’s stock worth $4,507,000 after purchasing an additional 23 shares during the period. Finally, Intergy Private Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company’s stock worth $208,000 after purchasing an additional 23 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president owned 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $478.61 on Friday. The stock has a market cap of $180.67 billion, a PE ratio of 27.68, a price-to-earnings-growth ratio of 2.47 and a beta of 0.77. The business has a 50-day simple moving average of $413.76 and a 200-day simple moving average of $470.22. The company has a quick ratio of 1.38, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.37 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.36%. Thermo Fisher Scientific’s payout ratio is 10.09%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMO. Stifel Nicolaus lowered their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Royal Bank Of Canada decreased their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a research report on Friday, July 11th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.